Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

About the trial

Sponsor

AbbVie (with Genentech, Inc.)

Tested

Venetoclax (drug), Azacitidine (drug), Placebo (drug)

Dates

Started 2020-09-10; completion 2027-07

Results posted

Not yet

Myelodysplastic Syndrome (MDS) is a group of disorders that gradually affect the ability of a person's bone marrow (semi-liquid tissue present in many bones like backbones) to produce normal blood cells. Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death from the disease itself. Symptoms of MDS include fatigue, shortness of breath, unusual paleness due to anemia (low red blood cell count), easy or unusual bruising, and red spots just beneath the skin caused by bleeding. The purpose of this study is to see how safe and effective venetoclax and azacitidine (AZA) combination are when compared to AZA and a placebo (contains no medi…

From ClinicalTrials.gov, last updated 2026-05-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $306,026 in research payments for this study in 2025 (99 payments).

Products named: Venclexta

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.